tradingkey.logo

Nanovibronix Inc

NAOV

0.850USD

+0.025+3.04%
Fechamento 08/04, 16:00ETCotações atrasadas em 15 min
623.99KValor de mercado
PerdaP/L TTM

Nanovibronix Inc

0.850

+0.025+3.04%
Mais detalhes de Nanovibronix Inc Empresa
NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
Informações da empresa
Código da empresaNAOV
Nome da EmpresaNanovibronix Inc
Data de listagemApr 24, 2015
CEODr. Doron Besser, M.D.
Número de funcionários15
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 24
Endereço969 Pruitt Piace
CidadeTYLER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal75703
Telefone19142333004
Sitehttps://nanovibronix.com/
Código da empresaNAOV
Data de listagemApr 24, 2015
CEODr. Doron Besser, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Director
Director
--
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Director
Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
986.00K
96.20%
New Zealand
19.00K
1.85%
Other
11.00K
1.07%
Europe
9.00K
0.88%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Alpha Capital Aktiengesellschaft
3.19%
Armistice Capital LLC
1.54%
Morgan Stanley & Co. LLC
0.53%
UBS Financial Services, Inc.
0.20%
Tower Research Capital LLC
0.04%
Other
94.50%
Investidores
Investidores
Proporção
Alpha Capital Aktiengesellschaft
3.19%
Armistice Capital LLC
1.54%
Morgan Stanley & Co. LLC
0.53%
UBS Financial Services, Inc.
0.20%
Tower Research Capital LLC
0.04%
Other
94.50%
Tipos de investidores
Investidores
Proporção
Holding Company
3.19%
Hedge Fund
1.58%
Research Firm
0.53%
Investment Advisor
0.20%
Individual Investor
0.03%
Other
94.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
2023Q1
41
69.83K
4.25%
-82.42K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Alpha Capital Aktiengesellschaft
82.47K
3.19%
+49.29K
+148.54%
May 16, 2025
Armistice Capital LLC
39.88K
1.54%
+39.88K
--
Mar 31, 2025
Morgan Stanley & Co. LLC
13.62K
0.53%
+13.62K
--
Mar 31, 2025
UBS Financial Services, Inc.
5.16K
0.2%
+1.41K
+37.64%
Mar 31, 2025
Tower Research Capital LLC
1.01K
0.04%
+465.00
+84.55%
Mar 31, 2025
Fashek (Christopher M)
341.00
0.01%
--
--
May 16, 2025
Northern Trust Investments, Inc.
102.00
0%
+102.00
--
Dec 31, 2023
Brown (Stephen Russell)
18.00
0%
--
--
May 16, 2025
Cassirer (Aurora)
9.00
0%
--
--
Mar 31, 2025
BofA Global Research (US)
7.00
0%
+4.00
+133.33%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Data
Tipo
Proporção
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
KeyAI